Of the 278 patients, 64 (23.0%) had underlying compensated cirrhosis, 39 (14.0%) had received therapies for hepatocellular carcinoma (HCC), and 13 (4.7%) had previous history of antiviral therapies with NS3/4A protease inhibitors such as telaprevir or simeprevir. Here, KRAS is linked to hepatocellular carcinoma.